Format

Send to

Choose Destination
Clin Genitourin Cancer. 2017 Apr;15(2):e205-e208. doi: 10.1016/j.clgc.2016.07.016. Epub 2016 Jul 22.

Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.

Author information

1
Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: mamatrana@ochsner.org.
2
Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
3
Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
4
Ochsner Cancer Institute, Ochsner Clinic Foundation, New Orleans, LA.
5
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
6
Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
7
Clinical Pharmacy Programs, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Abstract

BACKGROUND:

Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited.

PATIENTS AND METHODS:

We conducted a retrospective data analysis of records of consecutive metastatic non-clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012. Tumor response rate was assessed by a blinded radiologist using Response Evaluation Criteria in Solid Tumors version 1.1. PFS and overall survival (OS) times were estimated using Kaplan-Meier methods.

RESULTS:

Twenty-nine patients were identified with non-clear-cell metastatic RCC, 9 received pazopanib in the front-line setting, 20 in the salvage setting after progression of disease with other targeted therapies. Seven patients (24%) had papillary RCC, 4 (14%) had chromophobe, 5 (17%) had unclassified histopathology, and 13 (45%) had other subtypes including collecting duct, translocation Xp11.2, and various subtypes with sarcomatoid differentiation. All patients discontinued pazopanib before analysis. Median PFS was 8.1 months (95% CI, 5.7-NA [not available]) in the front-line group, and 4 months (95% CI, 2.1-9.9) in the salvage group. Median OS was 31 months (95% CI, 9.2-NA) in the front-line group, and 13.6 months (95% CI, 6.4-NA) in the salvage group.

CONCLUSION:

Pazopanib showed efficacy in patients with metastatic non-clear-cell RCC in the front-line and salvage settings. Toxicity was mild to moderate and manageable. Further studies are needed to evaluate pazopanib's role in non-clear-cell RCC in terms of efficacy and safety.

KEYWORDS:

Angiogenesis; Kidney cancer; Late relapse; Targeted therapy; Tyrosine-kinase inhibitor; mTOR inhibitor

PMID:
27568124
DOI:
10.1016/j.clgc.2016.07.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center